Comparison · NCT01208402-sae
Long-Acting Beta Blocker vs Esmolol: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Long-Acting Beta Blocker vs Esmolol: serious adverse events. Trial comparisons, record NCT01208402-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01208402-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0645 | 0.0179 | 0.207 | wilson | |
| Risk in group 2 | 0.0714 | 0.0198 | 0.226 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00691 | -0.169 | 0.145 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.903 | 0.136 | 5.99 | log | |
| Odds ratio, group 1 over group 2 | 0.897 | 0.118 | 6.83 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Long-Acting Beta Blocker than on Esmolol | 145 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Long-Acting Beta Blocker | Administer patient's routine oral long acting beta blocker on day of surgery (standard of care). | 2 | 31 | EG000 |
| Group 2 | Esmolol | Replace patient's routine oral long-acting beta blocker on day of surgery with a bolus of 500 mcg/kg at start of surgery, followed by a 4 minute infusion at 50 mcg/kg/min, titrating up to a maximum of 300mcg/kg/min to maintain heart rate and SBP within specified thresholds during the length of surgery and continuing through 12 hours post-operatively. | 2 | 28 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Esmolol for Treatment of Perioperative Tachycardia
- NCT number
- NCT01208402
- Phases
- PHASE3
- Conditions
- High-risk, Non-cardiovascular Surgeries
- Interventions
- Esmolol
- Lead sponsor
- Duke University
- Results first posted
- 2014-11-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01208402?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01208402-sae